JP2005516946A5 - - Google Patents

Download PDF

Info

Publication number
JP2005516946A5
JP2005516946A5 JP2003554189A JP2003554189A JP2005516946A5 JP 2005516946 A5 JP2005516946 A5 JP 2005516946A5 JP 2003554189 A JP2003554189 A JP 2003554189A JP 2003554189 A JP2003554189 A JP 2003554189A JP 2005516946 A5 JP2005516946 A5 JP 2005516946A5
Authority
JP
Japan
Prior art keywords
present
tegaserod
granulation
formulations
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003554189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516946A (ja
JP4718776B2 (ja
Filing date
Publication date
Priority claimed from EP01403339A external-priority patent/EP1321142A1/en
Application filed filed Critical
Publication of JP2005516946A publication Critical patent/JP2005516946A/ja
Publication of JP2005516946A5 publication Critical patent/JP2005516946A5/ja
Application granted granted Critical
Publication of JP4718776B2 publication Critical patent/JP4718776B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003554189A 2001-12-21 2002-12-20 5ht4部分アゴニスト医薬組成物 Expired - Fee Related JP4718776B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod
EP01403339.3 2001-12-21
PCT/EP2002/014674 WO2003053432A1 (en) 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions

Publications (3)

Publication Number Publication Date
JP2005516946A JP2005516946A (ja) 2005-06-09
JP2005516946A5 true JP2005516946A5 (https=) 2006-01-19
JP4718776B2 JP4718776B2 (ja) 2011-07-06

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003554189A Expired - Fee Related JP4718776B2 (ja) 2001-12-21 2002-12-20 5ht4部分アゴニスト医薬組成物

Country Status (31)

Country Link
US (2) US20050106236A1 (https=)
EP (2) EP1321142A1 (https=)
JP (1) JP4718776B2 (https=)
KR (1) KR100980144B1 (https=)
CN (1) CN100464749C (https=)
AR (1) AR037937A1 (https=)
AT (1) ATE320807T1 (https=)
AU (1) AU2002361198B2 (https=)
BR (1) BR0215148A (https=)
CA (1) CA2470668C (https=)
CO (1) CO5640102A2 (https=)
CY (1) CY1105559T1 (https=)
DE (1) DE60210139T2 (https=)
DK (1) DK1458377T3 (https=)
EC (1) ECSP105163A (https=)
EG (1) EG24194A (https=)
ES (1) ES2258171T3 (https=)
HU (1) HU226589B1 (https=)
IL (2) IL162451A0 (https=)
MX (1) MXPA04006157A (https=)
MY (1) MY139546A (https=)
NO (1) NO20042779L (https=)
NZ (1) NZ533585A (https=)
PE (1) PE20030872A1 (https=)
PL (1) PL369509A1 (https=)
PT (1) PT1458377E (https=)
RU (1) RU2322978C2 (https=)
SI (1) SI1458377T1 (https=)
TW (1) TWI260221B (https=)
WO (1) WO2003053432A1 (https=)
ZA (1) ZA200404467B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1314185B1 (it) * 1998-08-21 2002-12-06 Novartis Ag Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
SG168407A1 (en) 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050119328A1 (en) * 2003-03-25 2005-06-02 Hetero Drugs Limited Novel crysalline forms of tegaserod maleate
EP1629280A2 (en) * 2003-05-21 2006-03-01 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
AR045081A1 (es) * 2003-07-24 2005-10-12 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
ES2655435T3 (es) 2003-09-12 2018-02-20 Amgen Inc. Formulación de disolución rápida de cinacalcet
KR20060111675A (ko) * 2003-12-16 2006-10-27 테바 파마슈티컬 인더스트리즈 리미티드 테가세로드 염기 및 그것의 염의 다형태
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
LT2983667T (lt) 2013-04-12 2019-07-10 Ardelyx, Inc. Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CA3049678A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd 1−アザビシクロ[3.3.0]オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
IT1314185B1 (it) * 1998-08-21 2002-12-06 Novartis Ag Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
EA004872B1 (ru) * 1999-08-03 2004-08-26 ЛИЛЛИ АЙКОС эЛ-эЛ-Си β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ

Similar Documents

Publication Publication Date Title
JP2005516946A5 (https=)
JP2002532112A5 (https=)
JPH1072351A5 (https=)
AU2002348983A1 (en) Heat activated durable styling compositions comprising saccharide type compounds and film forming agents
CA2463947A1 (en) Montelukast granule formulation
NO20041452L (no) 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer.
NO20053115D0 (no) Fremgangsmate for fremstilling av 2'-forgrenede nukleosider.
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
ID30225A (id) Tablet matriks yang memungkinkan pelepasan yang diperlama dari gliklazida setelah pemberian secara oral
NO20024293D0 (no) Flekkfjernende tyggegummi og konfektblandinger, og fremgangsmåter for fremstilling av de samme
NO20043441L (no) Orodispersibel farmasoytisk sammensetning omfattende agomelatin
WO2004006858A3 (en) Compounds, compositions, and methods employing same
NO20042410L (no) Sammensetning som omfatter angiopoietinliknende protein 3, ANGPTL3 og fremgangsmate til anvendelse av samme
NO20055383D0 (no) Fremgangsmate for fremstilling av 1,3-propandiol
DK1499667T3 (da) Overtrækssammensætning til multiple hydrofile anvendelser
ATE362323T1 (de) Umhüllter kaugummi
DE60334379D1 (de) Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung
AP2004003154A0 (en) Novel perindopril salt and pharmaceutical compositions containing same.
IS6378A (is) Efnasambönd og samsetningar gegn dvergveirum, notkun þeirra til lyfjagerðar og efni til að framleiða þau
IS6956A (is) Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því
JP2005509503A5 (https=)
NO20052471D0 (no) Fremgangsmate for fremstilling av 3-metyltiopropanal.
NO20000456D0 (no) Fremgangsmåte for fremstilling av 1,2-dikloretan
ATE392644T1 (de) Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen
DE50309337D1 (de) Calcium enthaltende süssigkeit